TFP
RVNC

Tilia Fiduciary Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Tilia Fiduciary Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-600
Closed -$15.2K – 528
2023
Q2 		$15.2K Hold
600
– – 0.01% 330
2023
Q1 		$19.3K Hold
600
– – 0.02% 298
2022
Q4 		$11.1K Hold
600
– – 0.01% 354
2022
Q3 		$17K Hold
600
– – 0.02% 308
2022
Q2 		$9K Hold
600
– – 0.01% 395
2022
Q1 		$12K Hold
600
– – 0.01% 388
2021
Q4 		$10K Buy
+600
New +$10K 0.01% 417

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tilia Fiduciary Partners's RVNC Position: Q3 2023 in Review

Tilia Fiduciary Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 600 shares — an estimated $15.2K sold.

Tilia Fiduciary Partners first reported a position in RVNC in Q4 2021 and held it in 7 quarters. The position peaked at $19.3K in Q1 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Tilia Fiduciary Partners reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 600 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $15.2K.
  • Tilia Fiduciary Partners first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 7 quarters.
  • Tilia Fiduciary Partners's Revance Therapeutics, Inc. position peaked at $19.3K in Q1 2023.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2023, filed 10 Oct 2023.